Neurocompute scores biomedical literature, surfaces overlooked patterns, and turns Parkinson’s research into a living discovery terminal.
C grade · PMID 41976205
View analysis →C grade · PMID 41898215
View analysis →C grade · PMID 41967915
View analysis →C grade · PMID 41922490
View analysis →C grade · PMID 41926904
View analysis →C grade · PMID 41995153
View analysis →C grade · PMID 42000954
View analysis →C grade · PMID 41944312
View analysis →C grade · PMID 41980634
View analysis →C grade · PMID 41895390
View analysis →In a 6-OHDA rat model, oral spermidine (short- and long-term) normalized peripheral immune markers (reversed lymphopenia, increased CD4+ T cells and monocytes, raised IL-4/IL-10, lowered corticosterone) and reduced anhedonia and anxiety-like non-motor symptoms without biochemical toxicity.
This study provides translationally actionable evidence that spermidine supplementation can modulate peripheral immunity to alleviate PD-relevant non-motor symptoms, supporting repurposing and biomarker-guided clinical investigation.
In an MPTP-induced mouse model of Parkinson's, local Serping1 siRNA delivery preserved motor function and tyrosine hydroxylase levels in the substantia nigra and striatum while reducing pSer129-α-synuclein and inflammatory markers (COX-2, iNOS).
Positions SERPING1 as a modifiable inflammatory/complement-related target that reduces α-syn pathology and neurodegeneration in vivo, offering actionable therapeutic and repurposing opportunities (but requiring validation of delivery, mechanism, and safety).
In a cohort of older adults with type 2 diabetes initiating GLP-1 receptor agonists, a genetic score proxying higher systemic GLP1R expression was associated with a 22% lower hazard of incident Parkinson's disease and related disorders (HR 0.78), with consistent sensitivity analyses.
Provides mechanism-anchored genetic support that GLP1R-mediated pathways influence PDRD risk, strengthening rationale for GLP-1RA repurposing and for incorporating GLP1R-expression–based stratification or biomarkers into future Parkinson's prevention and therapeutic trials.
This review summarizes PET molecular imaging studies in late-life depression, reporting alterations across neurotransmitter systems, amyloid/tau pathology and neuroinflammation, and proposes next-generation PET tracers for glutamatergic signaling, mitochondrial function, HDAC activity, and…
Highlights imaging-accessible mechanisms—neuroinflammation, mitochondrial dysfunction, and glutamatergic dysregulation—that overlap with Parkinson's-relevant biology and could inform biomarker-driven target selection, patient stratification, or repurposing strategies for PD therapeutic discovery.
Using public transcriptomic data and machine learning, the authors derived a four-gene autophagy-related blood signature (PRKD1, CAMP, MCOLN3, ATG9B) that discriminates Parkinson's patients from controls (model AUC 0.845) and correlates with altered immune-cell infiltration, with RT-qPCR and plasma…
Provides a clinically accessible autophagy–immune linked biomarker panel with modest diagnostic performance and nominates mechanistically relevant genes (autophagy/lysosomal and immune-related) for follow-up as potential therapeutic targets or stratification tools, though prospective validation and…
Preclinical study demonstrating that a liposome-loaded microneedle patch delivers selegiline transdermally with sustained plasma exposure and produces improved motor behavior, antioxidant markers, dopamine levels, and histological signs of neuronal recovery in a rat Parkinson's model.
This work presents a translational drug‑delivery approach that could repurpose an approved MAO‑B inhibitor for more consistent, minimally invasive dosing and potential symptomatic neuroprotection, though therapeutic novelty is limited and findings are restricted to animal data without deep…
This retrospective real-world study of two US databases reports low rates of new-onset non-ICANS neurologic events after cilta-cel in RRMM patients—parkinsonism occurred in about 1% of patients with ≥4 prior lines of therapy and cranial nerve palsies in ~1–5%, with no parkinsonism seen in the 1–3…
While not mechanistic, the finding that CAR-T therapy can produce rare parkinsonism cases points to immune-mediated or neuroinflammatory routes to parkinsonism and is useful for surveillance and hypothesis generation for translational studies exploring inflammation-driven or iatrogenic PD…
This study identifies a nigro-subthalamic circuit (SNrGABA → SNcDA → STN) that selectively modulates contralateral mechanical (but not thermal) pain in mice and shows that STN D2 receptor activation alleviates mechanical hyperalgesia in both neuropathic and Parkinsonian models.
By defining a specific circuit and receptor (STN D2) that can be targeted to reduce Parkinsonian and neuropathic mechanical pain, the work provides an actionable mechanistic target with translational potential for repurposing D2-directed therapies or developing focal neuromodulation strategies for…
In a PD mouse model, transcranial magneto-acoustical stimulation (TMAS) targeted to M1 restored cortical–subthalamic balance, improved motor behavior, increased cortical activity and c-Fos, and elevated TH immunoreactivity in SNc without histological damage.
Presents a non‑invasive neuromodulation approach that modulates cortico‑subthalamic circuits and shows potential symptomatic benefit and dopaminergic marker enhancement, making it a promising translational lead for PD therapy pending mechanistic clarification and long‑term validation.
In a rotenone-induced zebrafish Parkinson's model, a carboxymethyl chitosan–phloroglucinol (CMC-PGL) conjugate improved locomotor behavior, restored brain dopamine levels, and reduced histological neuronal damage.
Provides early-stage in vivo evidence of a neuroprotective compound that rescues dopaminergic deficits linked to mitochondrial toxin exposure, making it a promising candidate for follow-up mechanistic studies and mammalian translational work.
Using a 6-OHDA rat model, the study correlates histology with transcranial sonography (TCS) features and applies cascaded super-resolution (WDSR + interpolation) and a ResNet18 classifier to improve TCS image quality (PSNR=30.67, SSIM=0.94) and stage early PD with 89% accuracy.
By creating a pathology-anchored, AI-enhanced noninvasive imaging biomarker for early PD staging, this approach could improve patient stratification and trial enrollment—boosting translational and diagnostic value even though it does not directly probe molecular therapeutic mechanisms.
In a zebrafish 6-OHDA larval model, an acetonic almond skin extract reduced ROS, increased GST activity, partially restored mitochondrial/apoptotic markers and tyrosine hydroxylase immunoreactivity at the higher dose, and modestly improved locomotor deficits, without mechanistic or mammalian…
Provides preliminary evidence that an agri-food polyphenol-rich extract has dopaminergic neuroprotective effects and could be a source of candidate bioactive compounds for PD discovery, but requires mechanistic studies, compound isolation, and translational testing in mammalian models.
This study applies a modified EfficientNet deep-learning model with reinforcement-learning-based optimization to classify Parkinson's disease versus healthy controls from MRI scans, reporting very high accuracy (~98%) and strong precision/recall metrics.
While the method could enhance diagnostic decision-support and early detection, it offers minimal mechanistic, biomarker, or therapeutic actionable insight for Parkinson's drug discovery or translational intervention development.
Comprehensive review linking DYRK1A to Parkinson's disease via GWAS associations, phosphorylation/interactions with numerous PD-relevant proteins (including SNCA, PRKN, RABs, TOM70), roles in axonal transport and neuroinflammation, and preliminary protective effects of DYRK1A inhibitors in models.
Identifies DYRK1A as a convergent, druggable kinase connecting multiple PD-relevant mechanisms and supports further preclinical evaluation and repurposing of DYRK1A modulators as potential neuroprotective therapies.
Water extract of Mucuna imbricata seeds was non‑toxic at tested doses and reduced carrageenan‑induced paw edema, oxidative stress (GSH, catalase, lipid peroxidation) and pro‑inflammatory cytokine gene expression in rats.
The extract's anti‑inflammatory and antioxidant effects are conceptually relevant to Parkinson's disease neuroinflammation and the Mucuna genus is a known L‑DOPA source, but absence of CNS, dopaminergic neuron, alpha‑synuclein, pharmacokinetic or PD‑model data limits immediate translational value…
Review of preclinical nose-to-brain biodegradable nanocarriers (lipid-, polymer-, hybrid-based nanoparticles, gels, nanoemulsions, sprays) for Alzheimer’s and Parkinson’s therapies, emphasizing pharmacokinetic/pharmacodynamic gains and formulation challenges for clinical translation.
Highlights a translational delivery approach that could substantially boost brain bioavailability and reduce systemic toxicity for PD drugs, making it a useful roadmap for advancing therapies if key nasal formulation and clinical testing barriers are solved.
BDCD is a comprehensive atlas of brain cell–cell communication integrating tens of thousands of single cells and spatial spots across multiple brain regions and diseases to reconstruct ~495,000 ligand–receptor events linked to genetic associations, pathways, and thousands of drugs/allosteric…
For Parkinson's research, BDCD enables hypothesis-driven identification of disease-relevant intercellular signaling pathways, prioritization of genetically linked ligand–receptor axes, and nomination of drug repurposing or target-modulation opportunities with spatial and cell-type resolution.
Humanized mice expressing HLA-DRB1*04:01 show reduced alpha-synuclein aggregation, less dopaminergic axon injury, and lower systemic inflammation compared with HLA-DRB1*04:02, with evidence of an activated microglial state consistent with enhanced alpha-synuclein clearance.
Provides experimental in vivo support that HLA genotype modulates alpha-synuclein pathology, highlighting an immune-genetic mechanism that could inform patient stratification, biomarker development, and immune- or microglia-directed therapeutic strategies for PD.
IL-6 deficiency exacerbates motor deficits and nigrostriatal degeneration in MPTP and α-synuclein A53T PD mouse models with stronger effects in females, and systemic recombinant IL-6 partially rescues motor function and striatal dopaminergic terminals.
Offers preclinical evidence that IL-6 signaling can be neuroprotective in PD and highlights recombinant IL-6 or modulation of IL-6 pathways—as well as sex-specific responses—as actionable avenues for therapeutic development, albeit with translational cautions around cytokine pleiotropy and systemic…
Prospective study in 184 PD patients produced a classifier combining substantia nigra hyperechogenicity (SNH), CRP, and homocysteine to distinguish PD cognitive stages (AUCs 0.729–0.823) and identified SNH, elevated CRP and Hcy as independent risk factors for cognitive impairment.
Moderate therapeutic relevance: the work links noninvasive imaging (SNH) with inflammation and homocysteine pathways, offering a stratification tool for trials and pointing to actionable avenues (anti‑inflammatory, Hcy‑lowering, iron‑modulating strategies), though it remains a…
